A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.

被引：0
|
作者：
Shapiro, Geoffrey
Supko, Jeffrey G.
Cho, Daniel C.
Hilton, John Frederick
Hadfield, Matthew
Pruitt-Thompson, Salida
Bordoli-Trachsela, Eveline
Zvereva, Nela
Wolanski, Andrew
Sato-DiLorenzo, Aya
Gotthardt, Susan
Fox, Edward A.
Verselis, Sigitas Jonas
Kumar, Ashok
Holden, Sylvia A.
Ram, Siya
Chafai-Fadela, Karima
Harding, Kimberly
Menon, Krishna E.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] KARD Sci, Beverly, MA USA
[5] Cellceutix, Beverly, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2627
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
    Shapiro, Geoffrey
    Mier, James Walter
    Hilton, John Frederick
    Gandhi, Leena
    Chau, Nicole G.
    Bullock, Andrea J.
    Supko, Jeffrey G.
    Verselis, Sigitas Jonas
    Murgo, Kayla
    Sze, Cameron
    Gotthardt, Susan
    Wolanski, Andrew
    Alexander, W. James
    Kumar, Ashok
    Holden, Sylvia Adell
    Chafai-Fadela, Karima
    Ram, Siya
    Menon, Krishna E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [3] Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors.
    Mileshkin, L. R.
    Rosen, L. S.
    Blumenkopf, T.
    Breazna, A.
    Darang, S.
    Davison, J.
    Gallo, J.
    Goldman, J. W.
    Wang, D. D.
    Zhang, S.
    Eckhardt, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [5] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K. Padda
    Yelena Krupitskaya
    Laveena Chhatwani
    George A. Fisher
    Alexander D. Colevas
    Melanie San Pedro-Salcedo
    Rodney Decker
    Jane E. Latz
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
  • [6] A phase I dose escalation and pharmacodynamic study of weekly administered AlbuleukinTM in patients with advanced solid tumors.
    Agarwala, SS
    Bukowski, RM
    Kirkwood, J
    Weiss, P
    Olencki, T
    Grzegorewski, KJ
    Melder, R
    Fox, RA
    Herpst, JM
    Gallant, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6231S
  • [7] A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
    LoRusso, Patricia
    Gounder, Mrinal M.
    Patel, Manish R.
    Yamamoto, Noboru
    Bauer, Todd Michael
    Laurie, Scott
    Grempler, Rolf
    Davenport, Teffany
    Geng, Junxian
    Rohrbacher, Maren
    Lahmar, Mehdi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [10] A phase I dose-escalation pharmacokinetic and pharmacodynamic study of INGN 241 (Ad-mda7) in patients with advanced solid tumors
    Cunningham, CC
    Richards, D
    Tong, A
    Zhang, Y
    Su, D
    Chada, S
    Mhashilkar, A
    Zhou-Yang, H
    Parker, K
    Wilson, D
    Nemunaitis, J
    Merritt, J
    Coffee, K
    CANCER GENE THERAPY, 2003, 10 : S2 - S3
12345